Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Vertex Pharmaceuticals paidMXN10,196 Mil more to buy back shares than it received from issuing new shares.
It receivedMXN0 Mil from issuing more debt.
It paidMXN0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedMXN0 Mil from paying cash dividends to shareholders.
It receivedMXN480 Mil on other financial activities.
In all, Vertex PharmaceuticalsspentMXN9,716 Mil on financial activities for the
three
months ended in Mar. 2026.
Vertex Pharmaceuticals (MEX:VRTX) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Vertex Pharmaceuticals's issuance of stock for the
three
months ended in Mar. 2026 was MXN0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Vertex Pharmaceuticals's repurchase of stock for the
three
months ended in Mar. 2026 was MXN-10,196 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Vertex Pharmaceuticals's net issuance of debt for the
three
months ended in Mar. 2026 was MXN0 Mil.
Vertex Pharmaceuticals receivedMXN0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Vertex Pharmaceuticals's net issuance of preferred for the
three
months ended in Mar. 2026 was MXN0 Mil.
Vertex Pharmaceuticals paidMXN0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Vertex Pharmaceuticals's cash flow for dividends for the
three
months ended in Mar. 2026 was MXN0 Mil.
Vertex Pharmaceuticals receivedMXN0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Vertex Pharmaceuticals's other financing for the
three
months ended in Mar. 2026 was MXN480 Mil.
Vertex Pharmaceuticals receivedMXN480 Mil on other financial activities.
Vertex Pharmaceuticals Cash Flow from Financing Related Terms
Vertex Pharmaceuticals Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Vertex Pharmaceuticals's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals Cash Flow from Financing Chart
Vertex Pharmaceuticals Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Vertex Pharmaceuticals's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-38,860 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of MXN-38,860 Mil mean?
Vertex Pharmaceuticals (MEX:VRTX) has a Cash Flow from Financing of MXN-38,860 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Cash Flow from Financing too high?
Vertex Pharmaceuticals' current Cash Flow from Financing is MXN-38,860 Mil. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Cash Flow from Financing compare to REGN and ALNY?
Vertex Pharmaceuticals' Cash Flow from Financing of MXN-38,860 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Cash Flow from Financing is MXN-38,860 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,914.24, compared to a current price of MXN8,474.00 — trading 4.9% below its estimated fair value. The current Cash Flow from Financing is MXN-38,860 Mil. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current Cash Flow from Financing is MXN-38,860 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN8,474.00 is trading 4.9% below its estimated GF Value™ of MXN8,914.24.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:VRTX:
Cash Flow from Financing: MXN-38,860 Mil
GF Value™: MXN8,914.24 vs. price of MXN8,474.00 (4.9% below fair value)
No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score
Get the complete analysis for MEX:VRTX
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VRTX has been successfully added to your 
